Why NovaBridge Biosciences’s (NBP) Stock Is Down 6.04%
As of Tuesday, September 01, NovaBridge Biosciences’s NBP share price has dipped by 6.04%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1clinical trial for multiple solid tumors. It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
Commentary & Analysis
Why NovaBridge Biosciences’s (NBP) Stock Is Down 5.77%
As of Tuesday, September 01, NovaBridge Biosciences’s NBP share price has dipped by 5.77%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why NovaBridge Biosciences’s (NBP) Stock Is Down 5.29%
As of Friday, August 28, NovaBridge Biosciences’s NBP share price has dipped by 5.29%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why NovaBridge Biosciences’s (NBP) Stock Is Down 8.42%
As of Wednesday, July 08, NovaBridge Biosciences’s NBP share price has dipped by 8.42%, which has investors questioning if this is right time to buy.Jenna Brashear
Why NovaBridge Biosciences’s (NBP) Stock Is Down 5.37%
As of Monday, July 06, NovaBridge Biosciences’s NBP share price has dipped by 5.37%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | NBP | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $207.6 | $288.9 | 27% |
|
| Shares Out (Mil) | 115.7 | 54.0 | 65% |
|
| Institutional Ownership | 68.6% | 93.1% | 42% |
|
| Float (Mil) | 64.6 | 41.4 | 53% |
|
| Beta | 1.48 | 0.94 | 82% |
|
| Avg Daily Volume (000s) | 312 | 480 | 52% |
|
| Price Change (52-week) |
(59.0%) | 59.9% | 12% |
|
| Growth | NBP | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (26.4%) | (10.1%) | 16% |
|
| EPS (5yr) | (23.5%) | 15.9% | 11 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (52.4%) | (15.6%) | 6% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | ($0.910) | ($0.630) | |
| Month Ago EPS | na | ($0.940) | ($1.060) | |
| # Rev Up | na | 1 | 1 | |
| # Rev Down | na | 0 | 0 | |
| Three Months Ago EPS | na | ($0.940) | ($1.060) | |
| Year/Year Chg | na | (1.3%) | (44.7%) | |
| Financials | NBP | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($118) | ($43) | 10% |
|
| EPS (TTM) | ($1.042) | ($1.500) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | ($46) | ($31) | 10% |
|
| Net Cash Flow (TTM) (Mil) | $25 | $2 | 64% |
|
| Long-Term Debt (Q1) (Mil) | $3 | $4 | 22% |
|
| Enterprise Value (Q1) (Mil) | $27 | $190 | 13% |
|
| Valuation | NBP | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.03 | 2.84 | 23% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | NBP | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (53.6%) | (47.7%) | 11% |
|
| ROE | (59.1%) | (55.0%) | 14% |
|
| Liabilities to Assets | 13.1% | 29.6% | 8% |
|
| F-Score | 1 | 3 | 1% |
|
NovaBridge Biosciences did not pass any screens on 9/2/2026.
